Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics ...Middle East

SAN FRANCISCO and SUZHOU, China, Oct. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and...

Hence then, the article about innovent announces results of a phase 2 study of picankibart anti il 23p19 antibody in plaque psoriasis showing efficacy in patients with prior inadequate response to il 17 biologics was published today ( Tuesday 29/10/2024 - 02:57 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics )

Also on site :

• Scammer posed as ‘well-known adult film star’ to defraud NFL and NBA players online from behind bars, feds say
• Video: What we know about Israel’s assault on southern Lebanon
• Sarah Michelle Gellar reveals who’s to blame for ‘Buffy’ reboot cancellation